Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus
- Abstract
- Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonimmunosuppressed patients. Patients present with lymphomatous effusions in serous cavities-pleura, pericardium, or peritoneum-without any identifiable tumor mass. PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts. A standard treatment for PEL has not yet been identified. We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.
- All Author(s)
- J. H. Won
; S. H. Han
; S. B. Bae
; C. K. Kim
; N. S. Lee
; K. T. Lee
; S. K. Park
; D. S. Hong
; D. W. Lee
; H. S. Park
- Issued Date
- 2006
- Type
- Article
- Keyword
- Primary effusion lymphoma; Human herpesvirus 8; High-dose chemotherapy
- Publisher
- Japanese Society of Hematology
- ISSN
- 0925-5710
- Citation Title
- International Journal of Hematology
- Citation Volume
- 83
- Citation Number
- 4
- Citation Start Page
- 328
- Citation End Page
- 330
- Language(ISO)
- eng
- DOI
- 10.1532/ijh97.A30510
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/3327
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.